AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of all claims in the application.

Listing of Claims

1. **(Currently Amended)** A method of treating an angiogenic disease in ~~treatment of~~ a host ~~with an angiogenic disease,~~ comprising contacting said host with a cephalotaxine in an amount sufficient to inhibit angiogenesis, wherein said angiogenic disease is not a solid tumor.

2. **(Original)** The method of claim 1 wherein the angiogenic disease is selected from the group consisting of an inflammatory disease, diabetic retinopathy, or macular degeneration.

3. **(Original)** The method of claim 2 wherein the inflammatory disease is selected from the group consisting of rheumatoid arthritis, osteoarthritis, asthma, and pulmonary fibrosis.

4. **(Original)** The method of claim 1 wherein the cephalotaxine comprises homoharringtonine (cephalotaxine, 4-methyl-2-hydroxy-2-(4-hydroxy-4- methyl pentyl) butanediocate ester).

5. **(Currently Amended)** The method of claim 1 wherein the cephalotaxine comprises a compound of the formula ~~homoharringtonine analog.~~



wherein R_1 is an ester or a substituted alkyl and wherein R_2 is an ester or a substituted alkyl.

6. **(Currently Amended)** The method of claim 1, wherein said cephalotaxine is administered by a route selected from the group consisting of ~~the cephalotaxine is administered to said host~~ oral, intravenous~~ly~~, topical~~ly~~, intravascular~~ly~~, intraperitoneal~~ly~~, intramuscular~~ly~~, intradermal~~ly~~, subcutaneous~~ly~~ and~~or~~ intraarterial~~ly~~.

7. **(Currently Amended)** A method of prophylactically treating an angiogenic disease in ~~prophylactic treatment of~~ a host, comprising contacting said host with a cephalotaxine in amount sufficient to inhibit the onset or progression of an angiogenic disease.

8. **(Original)** The method of claim 7, wherein the angiogenic disease is cancer.

9. **(Currently Amended)** The method of claim 8, wherein the cancer is characterized by cancer cells that have not yet been vascularized to form a solid tumor. ~~microtumors or micrometastatic cancer cells.~~

10. **(Original)** The method of claim 7, wherein the angiogenic disease is an angiogenic disease other than cancer.

11. **(Original)** The method of claim 7, wherein the angiogenic disease is selected from the group consisting of an inflammatory disease, diabetic retinopathy, or macular degeneration.

12. **(Original)** The method of claim 11, wherein the inflammatory disease is selected from the group consisting of rheumatoid arthritis, osteoarthritis, asthma, and pulmonary fibrosis.

13. **(Original)** The method of claim 7, wherein the cephalotaxine comprises homoharringtonine (cephalotaxine, 4-methyl-2-hydroxy-2-(4-hydroxy-4- methyl pentyl) butanediocate ester).

14. **(Currently Amended)** The method of claim 7, wherein the cephalotaxine comprises a compound of the formula ~~homoharringtonine analog.~~



wherein R_1 is an ester or a substituted alkyl and wherein R_2 is an ester or a substituted alkyl.

15. **(New)** The method of claim 5 or 14, wherein said cephalotaxine is selected from the group consisting of harringtonine, isoharrintonine, homoharringtonine, deoxyharringtonine, and acetylcephalotaxine.